Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Hepatic stellate cells (HSC) play a central role in the pathogenesis of liver fibrosis. Following liver injury, these cells proliferate and are activated to a profibrogenic myofibroblastic phenotype. In addition to increased matrix protein synthesis, there is evidence to indicate that these cells are able to regulate matrix degradation. In the early phases of their cellular activation, HSC release matrix metalloproteinases with the ability to degrade the normal liver matrix. When HSC are fully activated, there is a net down‐regulation of matrix degradation mediated by increased synthesis and extracellular release of tissue inhibitors of metalloproteinase (TIMP)‐1 and ‐2. These studies in cell culture have been complemented by in vivo studies of hepatic TIMP‐1 and TIMP‐2 gene expression. In advanced human liver disease of various aetiologies, there is increased TIMP‐1‐mRNA and protein and increased TIMP‐2‐mRNA in fibrotic liver compared with control liver. Temporal studies of progressive rat liver fibrosis caused by bile duct ligation or by carbon tetrachloride, indicate an important role for increased TIMP‐1 and TIMP‐2 expression in pathogenesis. Moreover, in a rat model of reversible liver fibrosis, matrix remodelling and resolution of liver fibrosis is closely associated, temporally, with a marked decrease in TIMP‐1 and TIMP‐2 expression. These combined cell culture and in vivo findings have led us to investigate the mechanisms of regulation of TIMP‐1 gene expression in hepatic stellate cells. Our recent data indicate that transcriptional regulation of TIMP‐1 gene expression in HSC is mediated via a mechanism which differs considerably from that previously identified in skin fibroblasts. We conclude that increased TIMP‐1 and TIMP‐2 expression by HSC plays an important role in the pathogenesis of liver fibrosis. This may represent an important therapeutic target in the design of anti‐fibrotic strategies for chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver
Benyon, R., Iredale, J., Goddard, S., Winwood, P., & Arthur, M. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608892 · Cited by 353
Self-citationIredale, J. P., Benyon, R. C., Arthur, M. J., Ferris, W. F., Alcolado, R., Winwood, P. J., Clark, N., & Murphy, G. (1996) · Hepatology · doi:10.1002/hep.510240129 · Cited by 324
Self-citation
Cited by
Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model
Weber, L. W. D., Boll, M., & Stampfl, A. (2003) · Critical Reviews in Toxicology · doi:10.1080/713611034 · Cited by 1,777
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Self-citationThe Bone Marrow Functionally Contributes to Liver Fibrosis
Russo, F. P., Alison, M. R., Bigger, B. W., Amofah, E., Florou, A., Amin, F., Bou–Gharios, G., Jeffery, R., Iredale, J. P., & Forbes, S. J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.036 · Cited by 483
Self-citationA significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis☆
Forbes, S. J., Russo, F. P., Rey, V., Burra, P., Rugge, M., Wright, N. A., & Alison, M. R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.025 · Cited by 436
Metadata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.